{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:35:29Z","timestamp":1772120129124,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Poznan Supercomputing and Network Centre","award":["437"],"award-info":[{"award-number":["437"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40291-021-00571-1","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T07:02:33Z","timestamp":1640070153000},"page":"105-116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Validation of HER2 Status in Whole Genome Sequencing Data of Breast Cancers with the Ploidy-Corrected Copy Number Approach"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-2723","authenticated-orcid":false,"given":"Marzena","family":"Wojtaszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafa\u0142","family":"St\u0119pie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9276-5486","authenticated-orcid":false,"given":"Alicja","family":"Wo\u017ana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7281-284X","authenticated-orcid":false,"given":"Maciej","family":"Piernik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0661-8800","authenticated-orcid":false,"given":"Pawel","family":"Sztromwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-3985","authenticated-orcid":false,"given":"Maciej","family":"D\u0105browski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7535-3316","authenticated-orcid":false,"given":"Micha\u0142","family":"Gniot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1127-9567","authenticated-orcid":false,"given":"S\u0142awomir","family":"Szyma\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3327-3334","authenticated-orcid":false,"given":"Maciej","family":"Socha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6651-4459","authenticated-orcid":false,"given":"Piotr","family":"Kasprzak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-5097","authenticated-orcid":false,"given":"Rafa\u0142","family":"Matkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9032-2315","authenticated-orcid":false,"given":"Pawe\u0142","family":"Zawadzki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"key":"571_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1126\/science.2992089","volume":"229","author":"CR King","year":"1985","unstructured":"King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science. 1985;229:974\u20136. https:\/\/doi.org\/10.1126\/science.2992089.","journal-title":"Science"},{"key":"571_CR2","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126:4278\u201388. https:\/\/doi.org\/10.1002\/cncr.33102.","journal-title":"Cancer"},{"key":"571_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"571_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jmoldx.2016.09.010","volume":"19","author":"DS Ross","year":"2017","unstructured":"Ross DS, Zehir A, Cheng DT, et al. Next-generation assessment of human epithelial growth factor receptor 2 (ERBB2) amplification status. J Mol Diagn. 2017;19:244\u201354. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.09.010.","journal-title":"J Mol Diagn"},{"key":"571_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/cyto.990080217","volume":"2","author":"CJ Cornelisse","year":"1987","unstructured":"Cornelisse CJ, van de Velde CJ, Caspers RJ, et al. DNA ploidy and survival in breast cancer patients. Cytometry. 1987;2:225\u201334. https:\/\/doi.org\/10.1002\/cyto.990080217 (PMID: 3582068).","journal-title":"Cytometry"},{"issue":"19 Suppl.","key":"571_CR6","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1158\/1538-7445.AM2014-2526","volume":"74","author":"ME Burkard","year":"2014","unstructured":"Burkard ME, Choudhary A, Robert FL, et al. Abstract 2526: Polyploidy: A new breast cancer subtype and a lead compound that targets it with high selectivity. Cancer Res. 2014;74(19 Suppl.):2526. https:\/\/doi.org\/10.1158\/1538-7445.AM2014-2526.","journal-title":"Cancer Res"},{"key":"571_CR7","doi-asserted-by":"publisher","first-page":"14932","DOI":"10.1038\/s41598-021-94332-z","volume":"11","author":"R Newcomb","year":"2021","unstructured":"Newcomb R, Dean E, McKinney BJ, et al. Context-dependent effects of whole-genome duplication during mammary tumor recurrence. Sci Rep. 2021;11:14932. https:\/\/doi.org\/10.1038\/s41598-021-94332-z.","journal-title":"Sci Rep"},{"key":"571_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12885-015-1035-1","volume":"15","author":"TVO Hansen","year":"2015","unstructured":"Hansen TVO, Vikesaa J, Buhl SS, et al. High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumors. BMC Cancer. 2015;15:35. https:\/\/doi.org\/10.1186\/s12885-015-1035-1.","journal-title":"BMC Cancer"},{"key":"571_CR9","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s12253-020-00844-w","volume":"26","author":"D Niu","year":"2020","unstructured":"Niu D, Li L, Yu Y, et al. Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers. Pathol Oncol Res. 2020;26:2577\u201385. https:\/\/doi.org\/10.1007\/s12253-020-00844-w.","journal-title":"Pathol Oncol Res"},{"key":"571_CR10","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.1038\/s41598-019-48212-2","volume":"9","author":"A Halilovic","year":"2019","unstructured":"Halilovic A, Verweij DI, Simons A, et al. HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study. Sci Rep. 2019;9:11679. https:\/\/doi.org\/10.1038\/s41598-019-48212-2.","journal-title":"Sci Rep"},{"issue":"7","key":"571_CR11","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jmoldx.2021.04.011","volume":"23","author":"P Roepman","year":"2021","unstructured":"Roepman P, de Bruijn E, van Lieshout S, et al. Clinical validation of whole genome sequencing for cancer diagnostics. J Mol Diagn. 2021;23(7):816\u201333. https:\/\/doi.org\/10.1016\/j.jmoldx.2021.04.011.","journal-title":"J Mol Diagn"},{"key":"571_CR12","doi-asserted-by":"publisher","first-page":"19123","DOI":"10.1038\/s41598-019-55636-3","volume":"9","author":"K Arora","year":"2019","unstructured":"Arora K, Shah M, Johnson M, et al. Deep whole-genome sequencing of 3 cancer cell lines on 2 sequencing platforms. Sci Rep. 2019;9:19123. https:\/\/doi.org\/10.1038\/s41598-019-55636-3.","journal-title":"Sci Rep"},{"key":"571_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature17676","volume":"534","author":"S Nik-Zainal","year":"2016","unstructured":"Nik-Zainal S, Davies H, Staaf J, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534:47\u201354. https:\/\/doi.org\/10.1038\/nature17676.","journal-title":"Nature"},{"key":"571_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/gcc.22431","volume":"56","author":"N Pfarr","year":"2017","unstructured":"Pfarr N, Penzel R, Endris V, et al. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes Cancer. 2017;56:255\u201365. https:\/\/doi.org\/10.1002\/gcc.22431.","journal-title":"Genes Chromosomes Cancer"},{"key":"571_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/his.14241","volume":"78","author":"RS Hoda","year":"2021","unstructured":"Hoda RS, Bowman AS, Zehir A, et al. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology\/College of American Pathologists HER2 testing guideline. Histopathology. 2021;78:498\u2013507. https:\/\/doi.org\/10.1111\/his.14241.","journal-title":"Histopathology"},{"issue":"7","key":"571_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002549","volume":"8","author":"Y Joly","year":"2012","unstructured":"Joly Y, Dove ES, Knoppers BM, Bobrow M, Chalmers D. Data sharing in the post-genomic world: the experience of the International Cancer Genome Consortium (ICGC) Data Access Compliance Office (DACO). PLoS Comput Biol. 2012;8(7): e1002549. https:\/\/doi.org\/10.1371\/journal.pcbi.1002549.","journal-title":"PLoS Comput Biol"},{"key":"571_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41586-019-1689-y","volume":"575","author":"P Priestley","year":"2019","unstructured":"Priestley P, Baber J, Lolkema MP, et al. Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 2019;575:210\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1689-y.","journal-title":"Nature"},{"key":"571_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"PJ Campbell","year":"2020","unstructured":"Campbell PJ, Getz G, Korbel JO, et al. Pan-cancer analysis of whole genomes. Nature. 2020;578:82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6.","journal-title":"Nature"},{"key":"571_CR19","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1093\/bioinformatics\/btq524","volume":"26","author":"L Goodstadt","year":"2010","unstructured":"Goodstadt L. Ruffus: a lightweight Python library for computational pipelines. Bioinformatics. 2010;26:2778\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btq524.","journal-title":"Bioinformatics"},{"key":"571_CR20","unstructured":"Picard toolkit. Broad Institute, GitHub repository. 2019. http:\/\/broadinstitute.github.io\/picard. Accessed 11 Dec 2021."},{"key":"571_CR21","unstructured":"Li H. Dana Farber Institute. SeqTk tool, GitHub repository. 2021. https:\/\/github.com\/lh3\/seqtk. Accessed 11 Dec 2021."},{"key":"571_CR22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17:10. https:\/\/doi.org\/10.14806\/ej.17.1.200.","journal-title":"EMBnet J."},{"key":"571_CR23","unstructured":"Sanger Institute. CancerIt tools, GitHub repository. 2021. https:\/\/github.com\/cancerit\/dockstore-cgpmap. Accessed 11 Dec 2021."},{"key":"571_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31:213\u20139. https:\/\/doi.org\/10.1038\/nbt.2514.","journal-title":"Nat Biotechnol"},{"key":"571_CR25","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.1038\/ncomms10001","volume":"6","author":"TS Alioto","year":"2015","unstructured":"Alioto TS, Buchhalter I, Derdak S, et al. A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nat Commun. 2015;6:10001. https:\/\/doi.org\/10.1038\/ncomms10001.","journal-title":"Nat Commun"},{"key":"571_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cpbi.17","volume":"56","author":"KM Raine","year":"2016","unstructured":"Raine KM, Loo P, Wedge DC, et al. ascatNgs: identifying somatically acquired copy-number alterations from whole-genome sequencing data. Curr Protoc Bioinform. 2016;56:15\u20139. https:\/\/doi.org\/10.1002\/cpbi.17.","journal-title":"Curr Protoc Bioinform"},{"key":"571_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, et al. The Ensembl variant effect predictor. Genome Biol. 2016;17:122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4.","journal-title":"Genome Biol"},{"issue":"11","key":"571_CR28","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1136\/jclinpath-2020-206998","volume":"74","author":"G Echejoh","year":"2021","unstructured":"Echejoh G, Liu Y, Chung-Faye G, et al. Validity of whole genomes sequencing results in neoplasms in precision medicine. J Clin Pathol. 2021;74(11):718\u201323. https:\/\/doi.org\/10.1136\/jclinpath-2020-206998.","journal-title":"J Clin Pathol"},{"issue":"2","key":"571_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/jmp2020013","volume":"2","author":"M Vives-Usano","year":"2021","unstructured":"Vives-Usano M, Garc\u00eda Pelaez B, Rom\u00e1n Llad\u00f3 R, et al. Analysis of copy number variations in solid tumors using a next generation sequencing custom panel. J Mol Pathol. 2021;2(2):123\u201334. https:\/\/doi.org\/10.3390\/jmp2020013.","journal-title":"J Mol Pathol."},{"key":"571_CR30","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1101\/gr.231100.117","volume":"8","author":"M Nattestad","year":"2018","unstructured":"Nattestad M, Goodwin S, Ng K, et al. Complex rearrangements and oncogene amplifications revealed by long-read DNA and RNA sequencing of a breast cancer cell line. Genome Res. 2018;8:1126\u201335. https:\/\/doi.org\/10.1101\/gr.231100.117.","journal-title":"Genome Res"},{"key":"571_CR31","doi-asserted-by":"publisher","first-page":"ix114","DOI":"10.1093\/annonc\/mdy441.006","volume":"29","author":"J Lee","year":"2018","unstructured":"Lee J, Franovic A, Rich TA, et al. Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population. Ann Oncol. 2018;29:ix114\u20135.","journal-title":"Ann Oncol"},{"key":"571_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12920-019-0643-z","volume":"12","author":"ND Pennock","year":"2019","unstructured":"Pennock ND, Jindal S, Horton W, et al. RNA-seq from archival FFPE breast cancer samples: molecular pathway fidelity and novel discovery. BMC Med Genom. 2019;12:195. https:\/\/doi.org\/10.1186\/s12920-019-0643-z.","journal-title":"BMC Med Genom"},{"key":"571_CR33","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1038\/s41598-020-64156-4","volume":"10","author":"RR Rawat","year":"2020","unstructured":"Rawat RR, Ortega I, Roy P, et al. Deep learned tissue \u201cfingerprints\u201d classify breast cancers by ER\/PR\/Her2 status from H&E images. Sci Rep. 2020;10:7275. https:\/\/doi.org\/10.1038\/s41598-020-64156-4.","journal-title":"Sci Rep"},{"key":"571_CR34","doi-asserted-by":"publisher","first-page":"8231","DOI":"10.1038\/s41598-019-44643-z","volume":"9","author":"F Zakrzewski","year":"2019","unstructured":"Zakrzewski F, de Back W, Weigert M, et al. Automated detection of the HER2 gene amplification status in fluorescence in situ hybridization images for the diagnostics of cancer tissues. Sci Rep. 2019;9:8231. https:\/\/doi.org\/10.1038\/s41598-019-44643-z.","journal-title":"Sci Rep"},{"key":"571_CR35","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41571-019-0252-y","volume":"16","author":"K Bera","year":"2019","unstructured":"Bera K, Schalper KA, Rimm DL, et al. Artificial intelligence in digital pathology: new tools for diagnosis and precision oncology. Nat Rev Clin Oncol. 2019;16:703\u201315. https:\/\/doi.org\/10.1038\/s41571-019-0252-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"571_CR36","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13244-019-0832-5","volume":"11","author":"E Montagnon","year":"2020","unstructured":"Montagnon E, Cerny M, Cadrin-Ch\u00eanevert A, et al. Deep learning workflow in radiology: a primer. Insights Imaging. 2020;11:22. https:\/\/doi.org\/10.1186\/s13244-019-0832-5.","journal-title":"Insights Imaging"},{"key":"571_CR37","doi-asserted-by":"publisher","first-page":"e00012","DOI":"10.1128\/JCM.00012-20","volume":"58","author":"BA Ford","year":"2020","unstructured":"Ford BA, McElvania E. Machine learning takes laboratory automation to the next level. J Clin Microbiol. 2020;58:e00012-20. https:\/\/doi.org\/10.1128\/JCM.00012-20.","journal-title":"J Clin Microbiol"},{"key":"571_CR38","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1186\/s13059-014-0431-1","volume":"32","author":"S-J Dawson","year":"2013","unstructured":"Dawson S-J, Rueda OM, Aparicio S, et al. A new genome-driven integrated classification of breast cancer and its implications. EMBO J. 2013;32:617\u201328. https:\/\/doi.org\/10.1186\/s13059-014-0431-1.","journal-title":"EMBO J"},{"issue":"7","key":"571_CR39","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.1999.17.7.1974","volume":"17","author":"WJ Timothy","year":"1999","unstructured":"Timothy WJ, Allen MG, Hadi Y, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2\/neu in breast cancer. J Clin Oncol. 1999;17(7):1974.","journal-title":"J Clin Oncol"},{"issue":"2","key":"571_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.4274\/ejbh.galenos.2021.2021-2-9","volume":"17","author":"H Sun","year":"2021","unstructured":"Sun H, Chen H, Crespo J, et al. Clinicopathological features of breast cancer with polysomy 17 and its response to neoadjuvant chemotherapy. Eur J Breast Health. 2021;17(2):128\u201336. https:\/\/doi.org\/10.4274\/ejbh.galenos.2021.2021-2-9.","journal-title":"Eur J Breast Health."},{"issue":"30","key":"571_CR41","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1200\/JCO.2007.13.4296","volume":"26","author":"I Vanden Bempt","year":"2008","unstructured":"Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008;26(30):4869\u201374. https:\/\/doi.org\/10.1200\/JCO.2007.13.4296.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-021-00571-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-021-00571-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T05:50:21Z","timestamp":1642485021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-021-00571-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1007\/s40291-021-00571-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.30.21258379","asserted-by":"object"}]},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"2 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the expenses were covered from the Poznan Supercomputing and Networking Center\u2019s \u2018computational grant\u2019 no. 437, titled <i>\u2018Molekularny mechanizm interakcji pomi\u0119dzy szlakami naprawy DNA w oporno\u015bci na chemioterapi\u0119\u2019<\/i>. Open access reimbursement will be granted based on Springer\u2019s Read and Publish agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Alicja Wo\u017ana, Pawel Sztromwasser, Maciej Piernik, and Pawe\u0142 Zawadzki are share owners in the company MNM Bioscience Inc. Marzena D. Wojtaszewska, Rafal St\u0119pien, Maciej D\u0105browski, and Micha\u0142 Gniot were employees of MNM Bioscience Inc. Marzena D. Wojtaszewska and Michal Gniot received conference reimbursements\/speaker honoraria from Novartis in the past. Other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The collection of all primary data used in this study was performed by international Genomic Consortia, which provided de-identified samples. Data collection and transmission was approved by local medical ethics committees during design of the original studies. No additional approvals are needed, and our study was reviewed and deemed exempt by the Adam Mickiewicz University Review Board. The protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki Declaration and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The written consent of each participant is in possession of Genomic Consortia. The primary data were collected in accordance with the standards set by the Declaration of Helsinki and the highest data security standards of ISO 27001. All necessary patient\/participant consent has been obtained and the appropriate institutional forms have been archived during the design of the original studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The investigators have adhered to controlled-access agreement conditions and obtained consent to publish the study results.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are openly available in the following repositories: Hartwig Medical Foundation at\n                      \n                      , which was acquired under data request number DR-169 and International Cancer Genome Consortium at\n                      \n                      , which was acquired under data request number DACO-6030. The Cancer Genome Atlas data were acquired via dbGaP platform (project phs000178.v11.p8) at:\n                      \n                      , under data request number #86794-3. The processed genomic data from 551 samples used for external validation were extracted from the publication by Nik-Zainal et al., 2016 (\n                      \n                      ) [file 1 and 4 of the ESM]. Secondary data that support the findings of this study generated by the authors are available in the ESM.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code for HER2\/<i>ERBB2<\/i> amplification classification is available at:\n                      \n                      .","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MW was responsible for the study design, manuscript preparation, and data analysis. AW is the main genomic data administrator and was responsible for the primary data acquisition. MP designed the computational framework for the machine learning approach. PS developed the pipeline and was responsible for bioinformatics support. MD refined the secondary data and helped to write the manuscript. MG conducted statistical analyses and verified the clinical actionability of genomic variants. SS curated medical data and made manuscript corrections. MS coordinated the statistical analysis. PK evaluated the concordance of the molecular and clinical data. RM provided expertise on molecular HER2 status assessment and evaluated the clinical data. PZ was the supervisor of the project, reviewed the methodology, and corrected and revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}